NSU-MD Faculty Articles
Tumor vaccines: from gene therapy to dendritic cells--the emerging frontier.
Publication Title
The Urologic clinics of North America
Publisher
W.B. Saunders Co.
ISSN
0094-0143
Publication Date
8-1-2003
Keywords
Cancer Vaccines, Carcinoma, Renal Cell, Dendritic Cells, Humans, Immunotherapy, Kidney Neoplasms, Neoplasm Metastasis
Abstract
Gene-modified tumor cells have been employed in a vaccination setting to trigger therapeutic antitumor immunity against metastatic renal cell carcinoma. Recent studies suggest that dendritic cells may be even more potent, because these cells can efficiently present tumor antigens to effector T cells, thereby circumventing the poor antigen-presenting properties of tumor cells. Proof of concept studies using antigen-loaded dendritic cells have been performed, establishing clear evidence of vaccine safety and bioactivity by stimulating immunologic and even clinical responses in cancer patients. Nevertheless, key aspects of such vaccination remain undefined. The critical challenge remains to understand fully the mechanisms of action and to further optimize dendritic cell vaccines to produce effective, durable, and, ultimately, therapeutic antitumor responses.
Volume
30
Issue
3
First Page
633
Last Page
643
Disciplines
Medicine and Health Sciences
NSUWorks Citation
Vieweg, Johannes and Dannull, Jens, "Tumor vaccines: from gene therapy to dendritic cells--the emerging frontier." (2003). NSU-MD Faculty Articles. 1.
https://nsuworks.nova.edu/hpd_md_facarticles/1
